Analyst Price Target is $7.25
▲ +262.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Regulus Therapeutics in the last 3 months. The average price target is $7.25, with a high forecast of $11.00 and a low forecast of $3.00. The average price target represents a 262.50% upside from the last price of $2.00.
Current Consensus is
Moderate Buy
The current consensus among 5 polled investment analysts is to moderate buy stock in Regulus Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More
